Patents by Inventor Su Yeon Ryu

Su Yeon Ryu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human monoclonal antibody that specifically binds to VCAM-1 and a composition for treating an inflammatory disease or a cancer comprising the same
    Patent number: 8715670
    Abstract: The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: May 6, 2014
    Assignee: Hanwha Chemical Corporation
    Inventors: Jung Tae Lee, Kyung Duk Moon, Ji Yong Yoon, Byung Je Sung, Dong Heon Lee, Il Sun Lee, Dong Eun Lee, Su Yeon Ryu, Young Woo Park, So Young Choi, Ji Hyun Park, Myeoung Hee Jang
  • Human recombinant monoclonal antibody that specifically binds to VCAM-1 and inhibits adhesion and transmigration between leukocytes and endothelial cells
    Patent number: 8623368
    Abstract: The present invention relates to a human recombinant monoclonal antibody that specifically binds to human Vascular Cell Adhesion Molecule-1 (VCAM-1) to inhibit adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, and a prophylactic and therapeutic composition for inflammatory disease or cancer comprising the same. The human recombinant monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human endothelial cell, and effectively inhibits VCAM-1-mediated adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, thereby being used for the prevention and treatment of inflammatory disease such as asthma and arthritis, transplant rejection, cardiovascular disease, and cancer.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: January 7, 2014
    Assignee: Hanwha Chemical Corporation
    Inventors: Jung Tae Lee, Kyung Duk Moon, Ji Yong Yoon, Byung Je Sung, Dong Heon Lee, Dong Eun Lee, Su Yeon Ryu, Hyun Bo Shim, Kyung Jae Kang
  • HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO VCAM-1 AND A COMPOSITION FOR TREATING AN INFLAMMATORY DISEASE OR A CANCER COMPRISING THE SAME
    Publication number: 20120308574
    Abstract: The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.
    Type: Application
    Filed: March 31, 2010
    Publication date: December 6, 2012
    Applicant: HANWHA CHEMICAL CORPORATION
    Inventors: Jung Tae Lee, Kyung Duk Moon, Ji Yong Yoon, Byung Je Sung, Dong Heon Lee, Il Sun Lee, Dong Eun Lee, Su Yeon Ryu, Young Woo Park, So Young Choi, Ji Hyun Park, Myeoung Hee Jang
  • Human Recombinant Monoclonal Antibody That Specifically Binds to VCAM-1 and Inhibits Adhesion and Transmigration Between Leukocytes and Endothelial Cells
    Publication number: 20120276091
    Abstract: The present invention relates to a human recombinant monoclonal antibody that specifically binds to human Vascular Cell Adhesion Molecule-1 (VCAM-1) to inhibit adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, and a prophylactic and therapeutic composition for inflammatory disease or cancer comprising the same. The human recombinant monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human endothelial cell, and effectively inhibits VCAM-1-mediated adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, thereby being used for the prevention and treatment of inflammatory disease such as asthma and arthritis, transplant rejection, cardiovascular disease, and cancer.
    Type: Application
    Filed: October 22, 2010
    Publication date: November 1, 2012
    Applicant: HANWHA CHEMICAL CORPORATION
    Inventors: Jung Tae Lee, Kyung Duk Moon, Ji Yong Yoon, Byung Je Sung, Dong Heon Lee, Dong Eun Lee, Su Yeon Ryu, Hyun Bo Shim, Kyung Jae Kang